CymaBay Therapeutics (CBAY) Tops Q2 EPS by 19c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q2 EPS of ($0.01), $0.19 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $31 million versus the consensus estimate of $11.38 million.

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c